LIVANOVA USA, INC.
HOUSTON, TX

LIVANOVA USA, INC., known previously as Cyberonics, Inc. (NASDAQ: CYBX), is a subsidiary entity under the parent company Cybrenex Holdings AG. The company operates within the medical technology sector, specializing in neuromodulation therapies. Specifically, LIVANOVA markets the Vagus Nerve Stimulation (VNS) Therapy system, an FDA-approved device used for the treatment of refractory epilepsy and treatment-resistant depression. This innovative therapy involves a surgically implanted medical device delivering electrical pulses to the vagus nerve. The company operates from its headquarters at 100 Cyberonics Blvd., Houston, TX, United States, but is officially registered under Florida with Broward County being the designated jurisdiction. The corporation maintains a focus on sound corporate governance and fiduciary responsibility, serving shareholders through strategic oversight of business operations as guided by their Board of Directors. The company was incorporated in Florida on February 22, 2001, and remains active under status 'FORP' (foreign private issuer). Historical events include reinstatement actions taken on October 5, 2018. LIVANOVA's most recent annual report for the year 2024 was filed on May 13, 2024. Cyberonics, Inc., as a prior designation of LIVANOVA USA, retains a robust operational framework through its key leadership positions held by Matthew Dodds (President), Annemarie Heins, and Sarah K Mohr (both Vice Presidents). For further company information, stakeholders are encouraged to visit the website at cyberonics.com.